



IFW

PATENT
ATTORNEY DOCKET NO. 50164/005002

Certificate of Mailing: Date of Deposit: July 20, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon
Printed name of person mailing correspondence

Susan M. Cannon
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alexis Borisy et al.	Art Unit:	1614
Serial No.:	10/677,664	Examiner:	Not yet assigned
Filed:	October 2, 2003	Customer No.:	21559
Title:	COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449. Copies of non-U.S. Patents documents are enclosed. Copies of communications from foreign patent offices in counterpart applications are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

July 20, 2004



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
50164.005002 Supplemental Information Disclosure Statement.doc

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50164/005002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Serial No.	10/677,664	
				Applicant	Alexis Borisy et al.	
				Filing Date	October 2, 2003	
				Group	1614	
				IDS Filed	July 20, 2004	
				Customer No.	21559	
U.S. PATENT DOCUMENTS						
Examiner's Initials	Patent Number	Publication or Issue Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,770,593 A	06/23/98	Grunicke et al.			
	6,569,853 B1	05/27/03	Borisy et al.			
	2002/0165261	11/07/02	Borisy			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 2004/06849	1/22/2004	W.I.P.O.			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Deger et al., "A New Therapeutic Approach for the Treatment of Cystic Echinococcosis: Percutaneous Albendazole Sulphoxide Injection without Reaspiration," Am. J. Gastroenterol. 95:248-254 (2000).					
	Lacey et al., "Activity of Benzimidazole Carbamates Against L1210 Mouse Leukaemia Cells: Correlation with <i>In Vitro</i> Tubulin Polymerization Assay," Biochem. Pharmacol. 34:3603-3605 (1985).					
	Makulu et al., "Effects of Pentamidine Upon Murine Leukemia and the Walker 256 Carcinoma (W256)," Am. Soc. for Pharmacol. Experimental Therapeutic, 16:105 (1974).					
	Pourgholami et al., " <i>In Vitro</i> Inhibition of Human Liver Cancer Cells by Albendazole," Proceedings of the American Association for Cancer Research Annual Meeting, 41:656 (2000).					
	Ram et al., "Synthesis and Biological Activity of Certain Alkyl 5-(Alkoxy carbonyl)-1H-Benzimidazole-2-Carbamates and Related Derivatives: A New Class of Potential Antineoplastic and Antifilarial Agents," J. Med. Chem., 35:539-547 (1992).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						